Found: 36
Select item for more details and to access through your institution.
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
- Published in:
- Drugs in R&D, 2017, v. 17, n. 3, p. 461, doi. 10.1007/s40268-017-0203-y
- By:
- Publication type:
- Article
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 4, p. N.PAG, doi. 10.1016/j.clgc.2024.102099
- By:
- Publication type:
- Article
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 3, p. N.PAG, doi. 10.1016/j.clgc.2024.102074
- By:
- Publication type:
- Article
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 2, p. 56, doi. 10.1016/j.clgc.2023.08.006
- By:
- Publication type:
- Article
Current Understanding of Urachal Adenocarcinoma and Management Strategy.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 1, p. 1, doi. 10.1007/s11912-020-0878-z
- By:
- Publication type:
- Article
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 2, p. 1096, doi. 10.3390/ijms24021096
- By:
- Publication type:
- Article
SARS‐CoV‐2 reinfection in a cancer patient with a defective neutralizing humoral response.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 4, p. 930, doi. 10.3390/jcm9040930
- By:
- Publication type:
- Article
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359231217958
- By:
- Publication type:
- Article
Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70182-3
- By:
- Publication type:
- Article
Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights.
- Published in:
- Biomolecules (2218-273X), 2021, v. 11, n. 1, p. 125, doi. 10.3390/biom11010125
- By:
- Publication type:
- Article
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1792, doi. 10.3390/cancers14071792
- By:
- Publication type:
- Article
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4522, doi. 10.3390/cancers13184522
- By:
- Publication type:
- Article
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 165, n. 2, p. 365, doi. 10.1007/s10549-017-4336-z
- By:
- Publication type:
- Article
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.
- Published in:
- ImmunoTargets & Therapy, 2020, v. 9, p. 273, doi. 10.2147/ITT.S240889
- By:
- Publication type:
- Article
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)".
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 12, p. 2291, doi. 10.1002/ijc.34246
- By:
- Publication type:
- Article
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 183, doi. 10.1177/1758834016683905
- By:
- Publication type:
- Article
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
- Published in:
- Clinical & Experimental Metastasis, 2024, v. 41, n. 5, p. 655, doi. 10.1007/s10585-024-10296-0
- By:
- Publication type:
- Article
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
- Published in:
- Therapeutic Advances in Urology, 2023, v. 15, p. 1, doi. 10.1177/17562872231187216
- By:
- Publication type:
- Article
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis.
- Published in:
- Therapeutic Advances in Urology, 2021, v. 13, p. 1, doi. 10.1177/17562872211053189
- By:
- Publication type:
- Article
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
- Published in:
- 2021
- By:
- Publication type:
- Letter
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.
- Published in:
- Therapeutic Advances in Urology, 2016, v. 8, n. 5, p. 319, doi. 10.1177/1756287216656811
- By:
- Publication type:
- Article
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
- Published in:
- Drug Design, Development & Therapy, 2016, v. 10, p. 2167, doi. 10.2147/DDDT.S104225
- By:
- Publication type:
- Article
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
- Published in:
- Oncology, 2017, v. 93, n. 5, p. 279, doi. 10.1159/000479154
- By:
- Publication type:
- Article
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2016, v. 21, n. 8, p. 988, doi. 10.1634/theoncologist.2016-0084
- By:
- Publication type:
- Article
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
- Published in:
- Oncologist, 2015, v. 20, n. 11, p. 1261, doi. 10.1634/theoncologist.2015-0171
- By:
- Publication type:
- Article
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44157-9
- By:
- Publication type:
- Article
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44157-9
- By:
- Publication type:
- Article
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-44157-9
- By:
- Publication type:
- Article